SEC 13F Intelligence

Managers / Q4 2019 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$138M
Q4 2019
Positions
52
Filings on Record
39
2019–present window
Filed
Feb 12, 2020
original filing

Summary

Birchview Capital, LP reported $138M in U.S.-listed holdings across 52 positions for Q4 2019.

The portfolio is heavily concentrated: BMY alone accounts for 36.3% of reported value.

Compared with Q3 2019, the fund opened 8 new positions and exited 6.

Portfolio Metrics

Turnover
+45.3%
vs prior filed quarter
Top-10 Concentration
+79.1%
share of reported value
Largest Position
+36.3%
Bristol Myers Squibb
New / Exited
8 / 6
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 62.8%Other: 34.6%Right: 1.5%MLP: 1.1%
  • Common Stock · 62.8% · $86M
  • Other · 34.6% · $48M
  • Right · 1.5% · $2M
  • MLP · 1.1% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
BMY CVR RTS 03/31/21NEW+699.6K699.6K+$2M$2M
CHEMOCENTRYX INCNEW+25.0K25.0K+$989,000$989,000
QGENQIAGEN NVNEW+20.0K20.0K+$676,000$676,000
BIOHAVEN PHARMACEUTICAL HOLDING CO LTDNEW+10.0K10.0K+$544,000$544,000
GOSSGOSSAMER BIO INCNEW+30.0K30.0K+$469,000$469,000
UTHRUNITED THERAPEUTICS CORPNEW+5.0K5.0K+$440,000$440,000
PGNYPROGYNY INCNEW+15.0K15.0K+$412,000$412,000
APELLIS PHARMACEUTICALS INCNEW+8.0K8.0K+$245,000$245,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2019

52 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM36.33%$50M778.6K
2ACCELERATE DIAGNOSTICS INCCOM26.83%$37M2.18M
3NBIXNEUROCRINE BIOSCIENCES INChistory →COM4.30%$6M55.0K
4QUIDEL CORPCOM2.66%$4M48.8K
5OXFORD IMMUNOTEC GLOBAL PLCCOM2.05%$3M170.3K
6VERMILLION INCCOM1.90%$3M3.22M
7BMY CVR RTS 03/31/21RIGHT1.53%$2M699.6K
8CONTRAFECT CORPCOM1.28%$2M2.83M
9EQM MIDSTRM PRTNERS LP LTDUNIT LTD PARTN1.12%$2M51.3K
10KARYOPHARM THERAPEUTICS INCCOM1.12%$2M80.0K
11SOLENO THERAPEUTICS INCCOM1.09%$2M510.6K
12BIIBBIOGEN INChistory →COM1.08%$1M5.0K
13HROWHARROW HEALTH INChistory →COM1.02%$1M180.0K
14VNDAVANDA PHARMACEUTICALS INCCOM0.95%$1M80.0K
15AMARIN CORP PLCSPONS ADR NEW0.92%$1M59.0K
16MASIMO CORPCOM0.92%$1M8.0K
17ARVNARVINAS INCCOM0.90%$1M30.0K
18BDQMALBIREO PHARMA INCCOM0.89%$1M48.0K
19DERMIRA INCCOM0.88%$1M80.0K
20G1 THERAPEUTICS INCCOM0.77%$1M40.0K
21INTERCEPT PHARMACEUTICALS INCCOM0.75%$1M8.3K
22ARENA PHARMACEUTICALS INCCOM0.73%$999,00022.0K
23XLRNACCELERON PHARMA INCCOM0.72%$990,00018.7K
24CHEMOCENTRYX INCCOM0.72%$989,00025.0K
25IMMUNOGEN INCCOM0.67%$919,000180.0K
26WRIGHT MEDICAL GROUP NVCOM0.66%$914,00030.0K
27MYGNMYRIAD GENETICS INCCOM0.59%$817,00030.0K
28QGENQIAGEN NVSHS0.49%$676,00020.0K
29ODONATE THERAPEUTICS INCCOM0.47%$649,00020.0K
30CORTCORCEPT THERAPEUTICS INCCOM0.44%$605,00050.0K
31ACADACADIA PHARMACEUTICALS INCCOM0.44%$599,00014.0K
32PIONEER NATURAL RESOURCES COCOM0.42%$575,0003.8K
33BIOHAVEN PHARMACEUTICAL HOLDING CO LTDCOM0.40%$544,00010.0K
34KALVISTA PHARMACEUTICALS INCCOM0.39%$534,00030.0K
35GOSSGOSSAMER BIO INCCOM0.34%$469,00030.0K
36UTHRUNITED THERAPEUTICS CORPCOM0.32%$440,0005.0K
37XNCRXENCOR INCCOM0.31%$423,00012.3K
38VYGRVOYAGER THERAPEUTICS INCCOM0.30%$419,00030.0K
39PGNYPROGYNY INCCOM0.30%$412,00015.0K
40AMICUS THERAPEUTICS INCCOM0.27%$370,00038.0K
41SIENTRA INCCOM0.26%$358,00040.0K
42LXRXLEXICON PHARMACEUTICALS INCCOM NEW0.24%$332,00080.0K
43VCYTVERACYTE INCCOM0.22%$301,00010.8K
44APELLIS PHARMACEUTICALS INCCOM0.18%$245,0008.0K
45ENCANA CORPCOM0.17%$232,00049.5K
46DICERNA PHARMACEUTICALS INCCOM0.16%$220,00010.0K
47CONTINENTAL RESOURCES INCCOM0.15%$206,0006.0K
48TGTXTG THERAPEUTICS INCCOM0.12%$167,00015.0K
49YIELD10 BIOSCIENCE INCCOM0.09%$130,000758.2K
50LIVENT CORPCOM0.06%$86,00010.0K
51WORKHORSE GROUP INCCOM0.06%$76,00025.0K
52BCRXBIOCRYST PHARMACEUTICALS INCCOM0.05%$69,00020.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.